日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial

认知障碍与绝经前和绝经后妇女的化学内分泌治疗与内分泌治疗:RxPONDER随机临床试验的二次分析

Kang, Irene M; Forschmiedt, Jamie K; Loch, Michelle M; Lew, Danika L; Barlow, William E; Gralow, Julie R; Meric-Bernstam, Funda; Albain, Kathy S; Hayes, Daniel F; Lin, Nancy U; Perez, Edith A; Goldstein, Lori J; Rastogi, Priya; Schott, Anne F; Baehner, Rick; Sharma, Priyanka; Tripathy, Debasish; Pusztai, Lajos; Hortobagyi, Gabriel N; Kalinsky, Kevin; Henry, N Lynn

Intimate Partner Violence in a Patient Population with Orthopaedic Trauma: Gender Disparities, Delayed Disclosures, and Poor Clinical Outcomes

骨科创伤患者群体中的亲密伴侣暴力:性别差异、延迟披露和不良临床结果

Fleming, Natalie; Pannozzo, Kiara; Bzovsky, Sofia; McKay, Paula; Gonsalves, Marc; Petrisor, Brad; Al-Asiri, Jamal; Ristevski, Bill; Williams, Dale; Johal, Herman; Gallant, Jodi; Pusztai, Kaitlyn; MacRae, Sarah; Renaud, Sara; Madden, Kim; Irish, Kimberley; Adili, Anthony; Valente, Giuseppe; Moro, Jaydeep; Khan, Moin; Khanna, Vickas; Sprague, Sheila

RISE UP for breast cancer 2024: conference highlights & takeaways

RISE UP for breast cancer 2024:会议亮点及要点

Glatt, Taylor; Leggat-Barr, Katherine; Seth, Nandini; Heditsian, Diane; van 't Veer, Laura; Pusztai, Lajos; Price, Elissa; Hylton, Nola; Formenti, Silvia; Rugo, Hope; Fejerman, Laura; Toriola, Adetunji T; Fabian, Carol; De Censi, Andrea; Grossman, Daniel; Olopade, Olufunmilayo; Jackson, Andrea; Horton, Sara; Rhoads, Kim; Lange, Carol; Borges, Virginia; Garner, Elizabeth; Garber, Judy; Yee, Douglas; Esserman, Laura

Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

在 II 期 I-SPY2 临床试验中,根据临床和分子特征分析 HR+/HER2- 高危早期乳腺癌 (EBC) 患者的病理完全缓解 (pCR) 率

Huppert, L A; Wolf, D; Yau, C; Brown-Swigart, L; Hirst, G L; Isaacs, C; Pusztai, L; Pohlmann, P R; DeMichele, A; Shatsky, R; Yee, D; Thomas, A; Nanda, R; Perlmutter, J; Heditsian, D; Hylton, N; Symmans, F; Van't Veer, L J; Esserman, L; Rugo, H S

Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer

蒽环类药物对基因组高危、淋巴结阴性、HR阳性/HER2阴性乳腺癌的影响

Chen, N; Freeman, J Q; Yarlagadda, S; Atmakuri, A; Kalinsky, K; Pusztai, L; Sparano, J A; Huo, D; Nanda, R; Howard, F M

GABA(A) receptor π forms channels that stimulate ERK through a G-protein-dependent pathway.

GABA(A)受体α形成通道,通过G蛋白依赖性途径刺激ERK

Wang Yueyue, Zhang Yalan, Li Wenxue, Salovska Barbora, Zhang Jianan, Li Tongqing, Li Hengyi, Liu Yansheng, Kaczmarek Leonard K, Pusztai Lajos, Klein Daryl E

Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study

早期癌症治疗后接受抗PD-(L)1疗法再治疗的影响因素:一项改良的德尔菲共识研究

Pusztai, Lajos; Sondak, Vernon K; Aguiar-Ibáñez, Raquel; Cappuzzo, Federico; Chouaid, Christos; Elder, Chris; Hirasawa, Yosuke; Ishida, Masaru; Jones, Robert; Lee, Seung Hyeun; Mizuno, Ryuichi; Nagata, Masayoshi; Okonji, David; Parente, Phillip; Shah, Bhavesh; Sun, Alexander; Ferreira, Dominihemberg; Spiteri, Carmel; Lauer, Andrea; Kaliasethi, Amrit; Kao, Carol; Kothari, Smita; McKendrick, Jan

Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers

激素受体阳性、HER2阴性/MammaPrint高表达2型乳腺癌与三阴性乳腺癌非常相似。

Rios-Hoyo, Alejandro; Xiong, Kaitlyn; Dai, Jiawei; Yau, Christina; Marczyk, Michal; Garcia-Milian, Rolando; Wolf, Denise M; Huppert, Laura A; Nanda, Rita; Hirst, Gillian L; Cobain, Erin F; van 't Veer, Laura J; Esserman, Laura J; Pusztai, Lajos

Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer

早期三阴性乳腺癌患者新辅助化疗-免疫治疗后复发的时间

Licata, Luca; Mariani, Marco; Viale, Giulia; Dent, Rebecca; Tolaney, Sara M; Schmid, Peter; Hamilton, Erika; Sotiriou, Christos; Pusztai, Lajos; Bianchini, Giampaolo

Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer

在早期三阴性乳腺癌患者接受度伐利尤单抗联合新辅助化疗的 I/II 期临床试验中,免疫相关不良事件与更好的无事件生存期相关。

Rios-Hoyo, A; Dai, J; Noel, T; Blenman, K R M; Park, T; Pusztai, L